← Back to patent-cliff list
丁苯酞注射液（石药集团）
Tier C — Watch / tradeButylphthalide Injection(Cspc Ouyi Pharma)
石药集团欧意药业有限公司
Originator
2010
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：Tandem pore domain potassium channels
Brand：恩必普
Indications (approved)：缺血性卒中、神经系统损伤
Regional status
US
-
EU
-
China
批准上市
2010-04-16
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Butylphthalide Injection(Cspc Ouyi Pharma)?
Approved indications include: 缺血性卒中, 神经系统损伤.
When does the Butylphthalide Injection(Cspc Ouyi Pharma) patent expire?
No public expiry year is available for Butylphthalide Injection(Cspc Ouyi Pharma) yet; this page updates once verified.
How do I get a quote for Butylphthalide Injection(Cspc Ouyi Pharma) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24